Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Transtema in connection with listing on Nasdaq Stockholm
Mandate

Vinge advises Transtema in connection with listing on Nasdaq Stockholm

September 17, 2021 Banking and Finance Capital Markets and Public M&A Employment and Benefits Intellectual Property IT, Telecommunications and Outsourcing

Vinge has advised Transtema in connection with its application for admission to trading on Nasdaq Stockholm’s main list.

The Nasdaq Companies Committee approved the application on 17 September 2021, and Transtema published the prospectus on the same day. The first day of trading is planned to take place on 29 September.

Vinge’s team primarily consisted of Anders Strid, Edin Agic (Project Manager), Jacob Benzov, Lina André (Banking and Finance), Anna Backman (Employment Law), Alexander Lindeberg (IP/IT) and Anna Högsten (IP/IT)

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026